On June 1st, 2024, BioPharmaSpec announced that it had recently purchased a range of new Mass Spectrometry<\/strong> instrumentation, including: Waters Select Series CYCLIC Ion Mobility Separation (IMS) High Definition LC-MS\/MS with ECD<\/strong>, SCIEX ZenoTOF 7600 LC-MS\/MS with EAD, Waters Xevo TQ Absolute<\/strong> and Waters Xevo G3 LC-MS\/MS Q-TOFs. <\/strong><\/p>\n To further support Clients with the provision of their first-class characterization services, BioPharmaSpec has also expanded its overall analytical instrumentation portfolio with the Bio-Techne (Protein Simple) Maurice Flex icIEF, CE-SDS and cIEF instrument, two Shimadzu PPSQ-53A Gas Phase Sequencers and a Wyatt DAWN Ambient 18 angle Multi Angle Light Scattering with Integrated DLS and Optilab dRI detector.\u00a0<\/strong><\/p>\n The instruments currently being installed and qualified across BioPharmaSpecs global laboratories further enhance BioPharmaSpecs already impressive mass spectrometric, chromatographic and spectroscopic service provision.<\/p>\n About BioPharmaSpec<\/strong><\/p>\n BioPharmaSpec is a CRO specializing in the structural characterization and physicochemical analysis of recombinant biopharmaceuticals, including biosimilars and biobetters<\/a>, monoclonal antibodies<\/a>, Antibody Drug Conjugates<\/a> (ADCs), gene therapy products<\/a> (i.e. AAV- based therapies), peptides<\/a>, oligonucleotides<\/a> and many more product types, with a focus on discovery, early and pre-clinical phases.<\/p>\n Contact:<\/strong> For more information, visit https:\/\/biopharmaspec.com\/<\/a><\/p>\n
Lindsay McGowan, Director of Business Development, BioPharmaSpec
Email: l.mcgowan@biopharmaspec.com<\/p>\n
![](\"https:\/\/ml-eu.globenewswire.com\/media\/MzhiODNmNjItMDg1Zi00MjViLTg5NTYtZmUzNTk5ZTQzNDgzLTEzMDM4NTY=\/tiny\/BioPharmaSpec.png\")
![\"Primary](\"https:\/\/ml-eu.globenewswire.com\/media\/98b6484d-57e1-4c62-a8be-93a65850d4e0\/small\/logo-jpg.jpg\"){kind=logo}
<\/a><\/p>\n